An early study showed a correlation between peripheral CD5+ lymphocytes and circulating anti-myelin basic protein (MBP) aAbs in human patients with (active) MS, especially with the disease duration and the number of gadolinium-enhancing lesions [221]. This evidence concerns the gene CD5 and myeloid sarcoma.